



BUSINESS & FINANCIAL UPDATE
FY & Q4 2021

March 14, 2022

Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma S.A., including estimates of target market opportunity, timing of planned clinical trials and results from those trials, regulatory strategy and timing of planned regulatory submissions, manufacturing capabilities and strategy for expansion of the ERYCAPS platform. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimates based upon the information available to ERYTECH Pharma S.A. as of the date of this presentation. The company's expectations regarding the effects of COVID-19 on the Company's trials and development may be incorrect. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statement.



Q4 2021 Business & Financial Update

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

Update on Clinical Programs

- Iman El Hariry, MD, PhD, Chief Medical Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers

Leader in Red Blood Cell-based Cancer Therapeutics



Proprietary ERYCAPS® technology allows reproducible encapsulation of therapeutics within red blood cells to improve therapeutic effect



Lead product candidate eryaspase (GRASPA®) demonstrated safety and efficacy in clinical trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer (PAC); Orphan Drug and Fast Track designations in ALL and PAC




Near-term commercial opportunity in ALL. Submission of BLA in hypersensitive ALL targeted in 1H 2022

Phase 2 trial in TNBC and Phase 1 IST in 1L PAC ongoing



Pipeline of preclinical programs with ERYCAPS platform, including new development with RBC-derived extracellular vesicles

Partnership with SQZ Biotech for immuno-modulation approach with RBC



Industrialized production: company operated cGMP production facilities in the United States and Europe (>5,000 clinical batches produced)




HQ in Lyon, France; office in Cambridge, MA, US

Listed on Nasdaq and Euronext (Ticker ERYP)



ERYCAPS®



Key Business Highlights



Phase 3 trial in second-line pancreatic cancer did not meet its primary endpoint
Interesting signal in subgroup of patients treated with irinotecan-based chemotherapy

Path to BLA
in ALL

Progress towards seeking approval of eryaspase for the treatment of ALL
patients who experienced hypersensitivity to pegylated asparaginase
BLA dossier near ready for filing pending FDA finalizing review of the remaining
information requests



Recommended Phase 2 dose determined in the rESPECT Phase 1 IST in 1L
pancreatic cancer); encouraging clinical activity observed in first patients



Process launched to evaluate strategic and partnering options
Valuable options in advanced stages of discussion



Q4 2021 Business & Financial Update

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

Update on Clinical Programs

- Iman El Hariry, MD, PhD, Chief Medical Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers


Phase 3 Trial in 2L Pancreatic Cancer



- The TRYbeCA-1 study did not meet the primary endpoint
 - However, all efficacy indicators (OS, PFS and DCR) showed nominal improvement with the addition of eryaspase
 - There was a trend towards improving OS in patients who received eryaspase and irinotecan-based therapy (FOLFIRI/NaI-IRI+5FU/LV) compared to control arm
- Well-balanced baseline characteristics and similar subsequent anti-cancer therapy
- Treatment was well tolerated, and the addition of eryaspase did not enhance the cytotoxicity of chemotherapy
- Full data analysis presented as late-breaking oral presentation at ASCO GI in January 2022
- Advisory meeting being held on January 31 to discuss potential path forward in pancreatic cancer, confirming the OS signal in the fluoropyrimidine & irinotecan subgroup is interesting and merits further investigation

Progress Towards Filing for Approval in Hypersensitive ALL

- **Hypersensitivity to *E-Coli*-asparaginase represents significant medical need**
 - Estimated annual treatable population: 15-20% of patients treated with pegylated asparaginase develop hypersensitivity (est 1,000 patients in the US)
 - One product approved in the US: Rylaze (Jazz Pharma), approved in June 2021
 - **NOPHO-sponsored Phase 2 trial:** Evaluation of safety and activity of GRASPA® (eryaspase) in combination with chemotherapy in ALL patients who developed hypersensitivities to pegylated asparaginase
 - Positive results presented at ASH Annual Meeting in December 2020
- “The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-ASNase”**



BLA Dossier Near Ready for Filing Pending OK to Submit


- Ongoing dialogue with FDA since mid 2020 (based on NOPHO interim data)
- Pre-BLA meeting with FDA held in June 2021
- Fast Track designation granted in July 2021
- BLA submission almost ready for filing pending finalization of review of information requests by the FDA and acceptance to file application
- Path to EU approval to be initiated in conjunction with progress in the US

1 IST in 1L Pancreatic Cancer

Investigator Sponsored Trial (IST) at Georgetown Lombardi Cancer Center evaluating combination of eryaspase and modified FOLFIRINOX

Patients (N ≈ 18)

- First-line (locally) advanced pancreatic cancer



Primary endpoint

- Safety/MTD

Key secondary endpoints

- Objective response rate
- Progression-free survival
- Overall survival

- Trial enrolling patients since January '21
- First dose cohort (75 U/kg) completed in Q1 '21; 2nd dose cohort (100 U/kg) completed in Q3 '21
- No Dose Limiting Toxicities (DLT): Maximum Tolerated Dose (MTD) determined at 100 U/kg
- Encouraging efficacy signals observed in first 10 patients (5/10 ORR and 10/10 DCR)
- Trial to continue enrolling up to 18 patients at dose of 100 U/kg
- Reporting of final results expected in 2H 2022; will be basis to evaluate further path in pancreatic cancer

Phase 2 Trial in Metastatic TNBC Closed for Further Enrollment

Randomized Phase 2 trial evaluating eryaspase in combination with chemotherapy versus chemotherapy alone in metastatic TNBC



Patients (N ≈ 64)

- Locally recurrent or metastatic TNBC
- Up to 1 prior treatment
- No BRCA1/2 mutation
- Measurable disease
- ECOG PS 0 or 1

Randomize 1:1

**Carboplatin/
gemcitabine
plus eryaspase**

**Carboplatin/
gemcitabine**

- Enrollment of patients halted after TRYbeCA-1 results
- Results of patients enrolled expected to be reported in **Q3 2022**



Q4 2021 Business & Financial Update

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer

Update on Clinical Programs

- Iman El Hariry, MD, PhD, Chief Medical Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers

FY2021 Cash Position and Cash Runway at Closing

- As of December 31, 2021: total cash position of €33.7 million (\$38.1 million) compared with €44.4 million (\$54.4 million) on December 31, 2020
- €10.7 million decrease in cash position in the 12-month period of 2021, with:
 - Net cash utilization of €57.1 million in Operating and Investing activities
 - Net cash generation of €44.7 million in Financing activities, including:
 - €34.6 million combined net proceeds from at-the-market (ATM) equity financing program (\$8M) and two Registered Direct offerings in April (\$30M) and December (\$7.85M) 2021
 - €11.4 million from the drawdown of four tranches of convertible notes (OCABSA)
 - Positive \$/€ currency exchange impact of €1.7 million
- Current cash position expected to fund planned operating expenses and current programs well into the third quarter of 2022.
- Given ongoing partnering discussions, need to present *proforma* FY2021 accounts per market regulation, to reflect the potential impact of a transaction on the Company's operations.
Consequently and given the time needed to prepare, audit and review proforma accounts with market regulators, the Company is postponing the reporting of its FY2021 financial results to a later date in April.

Key News Flow and Milestones Expected Over the Next 12 Months

- BLA submission of eryaspase in hypersensitive ALL (Q2 2022)
- Data from the randomized Phase 2 TRYbeCA-2 trial of eryaspase in TNBC (Q3 2022)
- Results of Phase 1 IST rESPECT in 1L pancreatic cancer (2H 2022)
- Update on strategic review and partnering process (1H 2022)



Q4 2021 Business & Financial Update

Introduction and Business Highlights

- Gil Beyen, Chief Executive Officer


Update on Clinical Programs

- Iman El Hariry, MD, PhD, Chief Medical Officer

Financial Update, Strategic Priorities & Next Steps

- Eric Soyer, Chief Financial & Chief Operating Officer

Questions & Answers



Thank you!

ERYTECH Pharma SA
60 Avenue Rockefeller
69008 Lyon
France

erytech 



ERYP
LISTED
EURONEXT

ERYTECH Pharma Inc
1 Main Street
Cambridge, MA 02142
USA

erytech 